S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
NASDAQ:IMCR

Immunocore Stock Forecast, Price & News

$21.93
+0.30 (+1.39%)
(As of 01/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$21.03
$22.40
50-Day Range
$18.94
$39.38
52-Week Range
$18.43
$61.99
Volume
206,740 shs
Average Volume
194,684 shs
Market Capitalization
$945.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive IMCR News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.


Immunocore logo

About Immunocore

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Headlines

Immunocore (NASDAQ:IMCR) Shares Gap Up to $18.94
January 24, 2022 |  americanbankingnews.com
Immunocore (NASDAQ:IMCR) Stock Price Up 4.3%
January 21, 2022 |  americanbankingnews.com
Immunocore (NASDAQ:IMCR) Shares Down 3.7%
January 20, 2022 |  americanbankingnews.com
Immunocore (NASDAQ:IMCR) Reaches New 12-Month Low at $20.56
January 19, 2022 |  americanbankingnews.com
Immunocore (NASDAQ:IMCR) Shares Down 8.6%
January 14, 2022 |  americanbankingnews.com
Immunocore Holdings is Now Oversold (IMCR)
January 13, 2022 |  nasdaq.com
Immunocore (NASDAQ:IMCR) Reaches New 12-Month Low at $25.30
January 13, 2022 |  americanbankingnews.com
Immunocore (NASDAQ:IMCR) Shares Gap Down to $30.39
January 10, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMCR
Fax
N/A
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
$38.67 million

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$945.78 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/25/2022
Next Earnings (Estimated)
3/24/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.59 out of 5 stars

Medical Sector

1045th out of 1,416 stocks

Biological Products, Except Diagnostic Industry

159th out of 206 stocks

Analyst Opinion: 3.4Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Immunocore (NASDAQ:IMCR) Frequently Asked Questions

Is Immunocore a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Immunocore stock.
View analyst ratings for Immunocore
or view top-rated stocks.

Are investors shorting Immunocore?

Immunocore saw a increase in short interest during the month of December. As of December 15th, there was short interest totaling 368,700 shares, an increase of 144.5% from the November 30th total of 150,800 shares. Based on an average trading volume of 63,300 shares, the short-interest ratio is presently 5.8 days. Approximately 0.9% of the company's shares are short sold.
View Immunocore's Short Interest
.

When is Immunocore's next earnings date?

Immunocore is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Immunocore
.

How were Immunocore's earnings last quarter?

Immunocore Holdings plc (NASDAQ:IMCR) issued its earnings results on Wednesday, November, 10th. The company reported ($0.95) earnings per share for the quarter, topping analysts' consensus estimates of ($1.10) by $0.15. The business had revenue of $8.17 million for the quarter, compared to the consensus estimate of $6.92 million.
View Immunocore's earnings history
.

What price target have analysts set for IMCR?

4 brokers have issued twelve-month price targets for Immunocore's stock. Their forecasts range from $40.00 to $65.00. On average, they expect Immunocore's share price to reach $54.75 in the next year. This suggests a possible upside of 149.7% from the stock's current price.
View analysts' price targets for Immunocore
or view top-rated stocks among Wall Street analysts.

Who are Immunocore's key executives?

Immunocore's management team includes the following people:
  • Dr. Bahija Jallal, CEO & Director (Age 59)
  • Mr. Brian R. Di Donato, CFO & Head of Strategy (Age 54)
  • Ms. Annelise Vuidepot Ph.D., CTO and Head of Pipeline & Platform Research
  • Clayton Robertson, Head of Investor Relations
  • Ms. Lily Hepworth, Gen. Counsel & Company Sec.
  • Ms. Debra Nielsen, Head of Communication
  • Ms. Frankie Webster, Chief People Officer
  • Dr. David Berman M.D., Ph.D., Head of R&D (Age 50)
  • Ms. JoAnn Suzich Ph.D., Head of Research
  • Mr. Koustubh Ranade Ph.D., Head of Translational Medicine

When did Immunocore IPO?

(IMCR) raised $199 million in an IPO on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies served as the underwriters for the IPO.

What is Immunocore's stock symbol?

Immunocore trades on the NASDAQ under the ticker symbol "IMCR."

How do I buy shares of Immunocore?

Shares of IMCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunocore's stock price today?

One share of IMCR stock can currently be purchased for approximately $21.93.

How much money does Immunocore make?

Immunocore has a market capitalization of $945.78 million and generates $38.67 million in revenue each year.

How many employees does Immunocore have?

Immunocore employs 2,020 workers across the globe.

What is Immunocore's official website?

The official website for Immunocore is www.immunocore.com.

Where are Immunocore's headquarters?

How can I contact Immunocore?

Immunocore's mailing address is 92 PARK DRIVE MILTON PARK ABINGDON, OXFORDSHIRE X0, OX14 4RY. The company can be reached via phone at 44-12-3543-8600 or via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.